Invitae And ArcherDX Will Merge To Create Comprehensive Cancer Testing Offering
The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.
You may also be interested in...
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.